Grant ID

BPN-6

Illness

Bipolar Disorder

Primary Drug/Intervention

zonisamide

Primary Dosage

N/A

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

BPN-6

Sample Size

60

Duration of Study Period for Each Subject

N/A

Outcome Measurements

N/A

Results

Sixty-two outpatients with bipolar disorders received adjunctive zonisamide in an 8 week acute phase and in a 48 week continuation phase. The trial was not blinded. Patients with manic symptoms at entry showed significant reductions in the CGI-BP and YMRS scales. Patiens with depressive symptoms showed significant reductions in the CGI-BP and IDS scales. Patients treated with zonisamide displayed a significant reduction in weight. 32% of patients discontinued zonisamide for worsening mood symptoms.

Publication

N/A

Link

N/A

PI Name

BPN-6 BPN-6

Degree

N/A

Center

N/A

Institution

N/A

Address

City or Town

N/A

State or Province

N/A

Zip or Postal Code

N/A

Country

N/A

Email Address

N/A